Verastem price target lowered to $14 from $16 at RBC Capital
RBC Capital analyst Gregory Renza lowered the firm’s price target on Verastem (VSTM) to $14 from $16 and keeps an Outperform rating on the ...
Plus Therapeutics announces FDA conditionally accepted name REYOBIQ
Plus Therapeutics (PSTV) announces the U.S. Food and Drug Administration, FDA, has conditionally accepted the Company’s new proprietary name, ...
Harvard Business Review4d
The Strategic Genius of Taylor Swift
A version of this article appeared in the March–April 2025 issue of Harvard Business Review. Kevin Evers is a senior editor at Harvard Business Review and the author of There’s Nothing Like ...